Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
JAZZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$99.06 - $138.27
Previous CloseN/A
Volume75.28K
Average Volume (3M)618.40K
Market Cap
$8.10B
Enterprise Value$10.62B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)19.3
Beta0.73
Next Earnings
Feb 25, 2025EPS Estimate
5.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.94
Shares Outstanding60,454,594
10 Day Avg. Volume837,556
30 Day Avg. Volume618,399
Standard Deviation0.08
R-Squared0.13
Alpha-0.00562
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.03
Price to Cash Flow (P/CF)5.10
P/FCF Ratio5.20
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda7.33
Forecast
1Y Price Target
$187.36Price Target Upside38.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Jazz Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsZani Phase 3 in first line GEA appears a relatively low risk catalyst that could be potentially transforming.
Intellectual PropertyPatent settlements with all outstanding Epidiolex patent challengers likely remove a patent trial as a risk factor.
Product PipelineSuccess in the 1L SCLC trial for Zepzelca suggests the product could grow for a few more years.
Bears Say
Legal IssuesThe 2H25 setup could be trickier, given OX2 data from ALKS and lawsuits including the anti-trust one vs AVDL.
Market CompetitionAnalyst believes the 1H25 setup for JAZZ heading into HORIZON GEA could meaningfully bring zani closer to JAZZ's $2B guided peak sales, but the competition remains fierce.
Patent ExpiryThe 2035 patents are strong, potentially delaying any generic settlement prior to 2025, but patent expiry remains a looming concern.
---
Ownership Overview
3.31% Insiders
26.42% Mutual Funds
35.10% Other Institutional Investors
7.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $99.06 and its highest was $138.27 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $8.10B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Feb 25, 2025 which is in 5 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $6.61 earnings per share for the quarter, beating the consensus estimate of $5.498 by $1.112.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 5.81.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,454,594 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.61 in its last earnings report, beating expectations of $5.498. Following the earnings report the stock price went up 6.75%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
---
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$187.36 (38.83% Upside)
$187.36 (38.83% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 219.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.79%
12-Months-Change
Fundamentals
Return on Equity
12.09%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strong performance across Jazz Pharmaceuticals' commercial portfolio, particularly in neuroscience and oncology, with record sales and positive clinical trial results for Zepzelca. However, there were challenges with Rylaze revenue due to updated treatment protocols and a trial setback for Epidiolex in Japan. Overall, the positive financial results and growth prospects balanced out the highlighted challenges.Read More>---
JAZZ Stock 12 Month Forecast
Average Price Target
$187.36
▲(38.83% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Supernus Pharmaceuticals
―
Heron Therapeutics
―
SAGE Therapeutics
―
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
17/26 ratings generated profit
1 Year Average Return
+5.05%
reiterated a buy rating 2 months ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 65.38% of your transactions generating a profit, with an average return of +5.05% per trade.
---